Matches in Nanopublications for { ?s ?p "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 19 of
19
with 100 items per page.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP331565.RASsmzTkCE6bNniHT65F2xCNYCia9RTDu-hCZOXIfvvMY130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP331565.RASsmzTkCE6bNniHT65F2xCNYCia9RTDu-hCZOXIfvvMY130_provenance.
- NP873059.RAUBpJtAUW4jjrYCuMiP0a4kwQ4B4IvS85xbIs6DmuTa8130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873059.RAUBpJtAUW4jjrYCuMiP0a4kwQ4B4IvS85xbIs6DmuTa8130_provenance.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP419927.RACxgKVGDAyQIkpLT5g44WryBS9Kt5uVbfjnoMeJAa65M130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419927.RACxgKVGDAyQIkpLT5g44WryBS9Kt5uVbfjnoMeJAa65M130_provenance.
- NP419929.RACp0daAOxlxhYMPW4WiOZxKGW46nBfcFaCPNj4Q5AoIY130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419929.RACp0daAOxlxhYMPW4WiOZxKGW46nBfcFaCPNj4Q5AoIY130_provenance.
- NP419939.RACUJUvm_bMBI1zaUJwH3rDqCrAvliXVMerRlzxJ3kh20130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419939.RACUJUvm_bMBI1zaUJwH3rDqCrAvliXVMerRlzxJ3kh20130_provenance.
- NP419926.RAfp7NCUtQ3pyQoc3kDmh-_Ywxmu7GylbUE2Z-9u9S6S4130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419926.RAfp7NCUtQ3pyQoc3kDmh-_Ywxmu7GylbUE2Z-9u9S6S4130_provenance.
- NP419930.RAcvI6o3-4_RGUbKGPuB3oglm6UsCG5ftIpRy7jf8v1gc130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419930.RAcvI6o3-4_RGUbKGPuB3oglm6UsCG5ftIpRy7jf8v1gc130_provenance.
- assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP913889.RAvpZOkt1B-hEg-yzOYe3TTnxqB0apBrpQ7hraFcuREzM130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913889.RAvpZOkt1B-hEg-yzOYe3TTnxqB0apBrpQ7hraFcuREzM130_provenance.
- NP605862.RAFV5R_JsTPUCAizklYi-6R-W0AFzenRMU5CWsAJGXeUI130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605862.RAFV5R_JsTPUCAizklYi-6R-W0AFzenRMU5CWsAJGXeUI130_provenance.
- NP419932.RALkon7QK3Ia9PB8mvOOebbqaI8psqeKGZGg2B42p9e4I130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419932.RALkon7QK3Ia9PB8mvOOebbqaI8psqeKGZGg2B42p9e4I130_provenance.
- NP781310.RAweAnfNT6siWO9z4GRwtzjuZrIwYayzaRcf0qMfSZ-rc130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781310.RAweAnfNT6siWO9z4GRwtzjuZrIwYayzaRcf0qMfSZ-rc130_provenance.
- NP978400.RA7Bd8yOYOl8dsN_KqZRkEni2g7b7oQslDNQ39Lb5bfaI130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978400.RA7Bd8yOYOl8dsN_KqZRkEni2g7b7oQslDNQ39Lb5bfaI130_provenance.
- NP419936.RA3Q8lWZbwnSbAuBEHMGJaFjmS6y8CS7ogbs7F5cA3oXg130_assertion description "[G-CSF therapy did not increase the risk of t-MDS/AML development in children with aplastic anemia over a median follow-up of 3.7 years]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419936.RA3Q8lWZbwnSbAuBEHMGJaFjmS6y8CS7ogbs7F5cA3oXg130_provenance.